Diadem Biotherapeutics wins Amgen's Golden Ticket award

By The Science Advisory Board staff writers

September 15, 2021 -- Diadem Biotherapeutics has been awarded the first Amgen Golden Ticket award, winning one year of lab space at BioLabs LA at the Lundquist Institute in West Carson, CA.

Diadem is a platform therapeutics company developing immunotherapies. Its cell-secreted nanovesicles are engineered to deliver signals that mimic natural cell-to-cell signaling. Diadem's approach enables modulation of targets that play a role in chronic inflammation, autoimmune diseases, and immune control of cancers, according to the firm.

The company also will receive mentoring from scientific and business leaders at Amgen and other facility benefits. Diadem is the first winner of the three-year sponsored competition.

The goal of the award is to support life science startups in the development of new therapies, medical devices, and diagnostics.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.